4d Molecular Therapeutics, Inc.
A maker of genetic medicines, 4D Molecular Therapeutics engineers custom viral delivery vehicles to treat diseases of the eye, lung, and heart. Founded in 2013 by a UC Berkeley professor and a biotech entrepreneur who met at a university innovation hub, the company got its start in a garage incubator. Its name reflects the four dimensions of optimization its scientists pursue when designing the adeno-associated virus vectors that carry therapeutic genes into the body.
Granted 50.0K · Sold 185.7K
Granted 1.1K · Sold 390
Granted 9.8K · Sold 9.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kirn DavidSee Remarks, Director · 5 transactions | -22% | 825.8K | 50.0K | — | 185.7K |
| Gupta AshooVP, Finance and Controller · 4 transactions | +1.1% | 47.1K | 1.1K | — | 390 |
| Bizily ScottChief Legal Officer · 2 transactions | +412.7% | 18.4K | 9.8K | — | 9.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -195.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.